SEC filings and other documents

Sustained double-digit growth, biosimilar expansion, and new plasma sales drive strong outlook.

Record revenue and EBITDA growth in H1 2026, with strong outlook and sustained profitability.

Q1 2026 delivered stable results and strong outlook, with growth in plasma and biosimilars.

Double-digit revenue and profit growth in 2025, with robust 2026 guidance and portfolio expansion.

Phase 3 Inhaled AAT trial halted for futility; cost savings to boost EBITDA and growth outlook.

Sustained double-digit growth fueled by specialty plasma therapies and global expansion.

Double-digit growth, new plasma centers, and a leading AATD program drive future expansion.

Double-digit revenue and profit growth in Q3 2025, with strong outlook and portfolio expansion.

Strong financial growth, product innovation, and global expansion drive future outlook.

Specialty plasma growth, global expansion, and innovation drive strong financial performance.

Profitable growth in Q2/H1 2025, with raised guidance and expanding biosimilar and plasma operations.

Double-digit revenue and profit growth in Q1 2025, with strong guidance and portfolio expansion.

Double-digit growth, new plasma centers, and late-stage pipeline drive robust outlook.

Record revenue and EBITDA in 2024, with strong 2025 growth and special dividend announced.

Double-digit growth in revenue and profit, with raised 2024 EBITDA guidance and strong outlook.

Double-digit growth, new plasma centers, and a pivotal inhaled AAT trial drive future upside.

Double-digit revenue and profit growth in H1 2024, with strong US sales and robust outlook.